TAP Pharmaceutical Products has agreed to pay the government a record $875 million to settle extensive civil and criminal charges of illegally marketing and manipulating the costs of Lupron, a prostate cancer drug, under the Medicare and Medicaid programs, the Department of Justice (DOJ) announced October 3, 2001.
» more
|